Halliburton Company vs BIO-TECHNE Corp — how do they compare? Halliburton Company trades at $32.44 (market cap $26.45B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Halliburton Company is far larger — about 2.3× BIO-TECHNE Corp's market cap, and Halliburton Company pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and BIO-TECHNE Corp for 63 Days on average.
| HAL | TECH | |
|---|---|---|
Market Cap | $26.45B | $11.37B |
Volume | 11,229,274 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $42.98 | $72.61 |
52-Week Low | $21.82 | $43.31 |
Typical Hold Time | 89 Days | 63 Days |
Enterprise Value | $32.60B | $11.40B |
Dividend Yield | 2.14% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.57, down 0.46% on the day, amid a bearish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights expansion in Venezuela and a major contract win in Cyprus, signaling growth initiatives. Financials show solid profitability with a net income margin of 7.16% and a P/E ratio of 16.62, though 2025 revenue dipped slightly to $22.18 billion.
The outlook is supported by strong analyst consensus with a $43.11 price target and 73% buy ratings, but risks include oil price volatility and execution challenges in new markets. Cash flow trends have been mixed, with 2025 net cash flow negative $412 million, though 2026 projects a return to positive territory.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →